Adult acute lymphoblastic leukaemia

Ferlay J, Bray F, Sankila R, et al. Cancer incidence, mortality and prevalence in the European Union. Lyon: IARC Press; 1999. Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide, version 1.0. Lyon: IARC Press, IARC Cancer Base No. 5; 2001. Stewart BW, Kleihus P, editors. World cancer report. Lyon: IARC Press; 2003. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol. VIII. IARC Scientific Publication No. 155. Lyon: International Agency for Research on Cancer; 2002. Carli, 1998, Variation in survival of adult patients with haematological malignancies in Europe since 1978. EUROCARE Working Group, Eur. J. Cancer, 34, 2253, 10.1016/S0959-8049(98)00339-6 Berrino F, Capocaccia R, Coleman MP, Esteve J, Gatta G, Hakulinen T, et al. Survival of cancer patients in Europe: the EUROCARE-3 Study. Ann Oncol 2003. Micheli, 2002, Cancer prevalence in European registry areas, Ann. Oncol., 13, 840, 10.1093/annonc/mdf127 Noshchenko, 2002, Radiation-induced leukemia risk among those aged 0–20 at the time of the Chernobyl accident: a case-control study in the Ukraine, Int. J. Cancer, 99, 609, 10.1002/ijc.10406 Smith MA, Gloecker Ries LA, Gurney JG, Ross JA. Leukaemia in cancer incidence and survival among children and adolescents: United Stated SEER Program 1975–1995. NCI, SEER Pediatric Cancer Monograph; 1999. Little J. Epidemiology of childhood cancer. IARC Scientific Publication No. 149, Lyon: International Agency for Research on Cancer; 1999. Lai, 2000, Pathologic diagnosis of acute lymphocytic leukemia, Hematol. Oncol. Clin. North Am., 14, 1209, 10.1016/S0889-8588(05)70183-0 Bennett, 1976, Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group, Br. J. Haematol., 33, 451, 10.1111/j.1365-2141.1976.tb03563.x Brunning RD, Flandrin G, Borowitz M. Precursor B lymphoblastic leukaemia/lymphoblastic lymphoma (precursors B-cell acute lymphoblastic leuaemia). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of the hhaematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 111–4. Brunning RD, Flandrin G, Borowitz M. Precursor T lymphoblastic leukaemia/lymphoblastic lymphoma (precursors T-cell acute lymphoblastic leuaemia). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of the hhaematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 115–7. Kim, 1998, Acute lymphoblastic leukemia with maturation--a new entity with clinical significance, Leukemia, 12, 875, 10.1038/sj.leu.2401032 Hurwitz, 1992, Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells, Leukemia, 6, 233 Huh, 2000, Immunophenotypes in adult acute lymphocytic leukemia. Role of flow cytometry in diagnosis and monitoring of disease, Hematol. Oncol. Clin North Am., 14, 1251, 10.1016/S0889-8588(05)70185-4 Coustan-Smith, 1998, Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia, Lancet, 351, 550, 10.1016/S0140-6736(97)10295-1 Janossy, 1989, The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases, Leukemia, 3, 170 Czuczman, 1999, Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364, Blood, 93, 3931 Khalidi, 1999, Adult precursor-B acute lymphoblastic leukemia with translocations involving chromosome band 19p13 is associated with poor prognosis, Cancer Genet. Cytogenet., 109, 58, 10.1016/S0165-4608(98)00153-8 De Waele, 2001, Growth factor receptor profile of CD34+ cells in AML and B-lineage ALL and in their normal bone marrow counterparts, Eur. J. Haematol., 66, 178, 10.1034/j.1600-0609.2001.00320.x Bene, 1995, Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia, 9, 1783 Thalhammer-Scherrer, 2002, The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination, Am. J. Clin. Pathol., 117, 380, 10.1309/C38D-D8J3-JU3E-V6EE Lenormand, 1998, PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucemies, Leuk. Lymphoma, 28, 329, 10.3109/10428199809092688 Lemmers, 2000, Fine characterization of childhood and adult acute lymphoblastic leukemia (ALL) by a proB and preB surrogate light chain-specific mAb and a proposal for a new B cell ALL classification, Leukemia, 14, 2103, 10.1038/sj.leu.2401932 Lim, 1999, Molecular and phenotypic spectrum of de novo Philadelphia positive acute leukemia, Int. J. Mol. Med., 4, 665 Pajor, 2000, The existence of lymphoid lineage restricted Philadelphia chromosome-positive acute lymphoblastic leukemia with heterogeneous bcr-abl rearrangement, Leukemia, 14, 1122, 10.1038/sj.leu.2401794 Keyhani, 2000, Increased CD38 expression is associated with favorable prognosis in adult acute leukemia, Leuk. Res., 24, 153, 10.1016/S0145-2126(99)00147-2 Geijtenbeek, 1999, High frequency of adhesion defects in B-lineage acute lymphoblastic leukemia, Blood, 94, 754, 10.1182/blood.V94.2.754 Greaves, 1981, Phenotypic heterogeneity and cellular origins of T cell malignancies, Leuk. Res., 5, 281, 10.1016/0145-2126(81)90001-1 Rieder, 1998, High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia, Leukemia, 12, 1473, 10.1038/sj.leu.2401127 Bloomfield, 1986, Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia, Blood, 67, 415, 10.1182/blood.V67.2.415.415 Pui, 1990, Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia, Blood, 76, 1449, 10.1182/blood.V76.8.1449.1449 Walters, 1990, The importance of cytogenetic studies in adult acute lymphocytic leukemia, Am. J. Med., 89, 579, 10.1016/0002-9343(90)90175-D Secker-Walker, 1997, Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party, Br. J. Haematol., 96, 601, 10.1046/j.1365-2141.1997.d01-2053.x GFCH. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood 1996;87:3135–42. Wetzler, 1999, Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience, Blood, 93, 3983 Wetzler, 2000, Cytogenetics in adult acute lymphocytic leukemia, Hematol. Oncol. Clin. North Am., 14, 1237, 10.1016/S0889-8588(05)70184-2 Harrison, 2001, The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management, Br. J. Haematol., 113, 3, 10.1046/j.1365-2141.2001.02643.x Kolomietz, 2001, Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis, Blood, 97, 3581, 10.1182/blood.V97.11.3581 Pedersen, 2001, Cytogenetic aberrations in adult acute lymphocytic leukemia: optimal technique may influence the results, Cancer Genet. Cytogenet., 128, 7, 10.1016/S0165-4608(01)00388-0 Kasprzyk, 1999, Investigation of clonal involvement of myeloid cells in Philadelphia-positive and high hyperdiploid acute lymphoblastic leukemia, Leukemia, 13, 2000, 10.1038/sj.leu.2401580 Cobaleda, 2000, A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia, Blood, 95, 1007, 10.1182/blood.V95.3.1007.003k35_1007_1013 Tabernero, 2001, Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10* CD34* CD13 and CD38 expresssion, Leukemia, 15, 406, 10.1038/sj.leu.2402060 Hagemeijer, 1987, Characterization of the blast cells in acute leukemia with translocation (4;11): report of eight additional cases and of one case with a variant translocation, Leukemia, 1, 24 Schardt, 1992, Acute lymphoblastic leukemia with the (4;11) translocation: combined cytogenetic, immunological and molecular genetic analyses, Leukemia, 6, 370 Secker-Walker, 1992, Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia, Leukemia, 6, 363 Borowitz, 1993, Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study, Blood, 82, 1086, 10.1182/blood.V82.4.1086.1086 Privitera, 1992, Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia, Blood, 79, 1781, 10.1182/blood.V79.7.1781.1781 Schneider, 2000, New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases, Blood, 96, 2543, 10.1182/blood.V96.7.2543 Lange, 1992, Pediatric leukemia/lymphoma with t(8;14)(q24;q11), Leukemia, 6, 613 Faderl, 1998, Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia, Blood, 91, 3995, 10.1182/blood.V91.11.3995 Dabaja, 1999, Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence associations and implications, Leukemia, 13, 869, 10.1038/sj.leu.2401430 Mancini, 2002, Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia, Leukemia, 16, 2055, 10.1038/sj.leu.2402640 Ribera, 2002, Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial, Haematologica, 87, 154 Trueworthy, 1992, Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study, J. Clin. Oncol., 10, 606, 10.1200/JCO.1992.10.4.606 Heerema, 1999, Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children’s cancer group, Blood, 94, 4036 Langerak, 2001, Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations, Blood, 98, 165, 10.1182/blood.V98.1.165 Cole-Sinclair, 1994, Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia, Baillieres Clin. Haematol., 7, 183, 10.1016/S0950-3536(05)80200-8 Faderl, 2000, Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia, Hematol. Oncol. Clin. North Am., 14, 1267, 10.1016/S0889-8588(05)70186-6 Ferrando, 2000, Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia, Semin Hematol., 37, 381, 10.1016/S0037-1963(00)90018-0 Heisterkamp, 1985, Structural organization of the bcr gene and its role in the Ph’ translocation, Nature, 315, 758, 10.1038/315758a0 Biondi, 1993, Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation, Blood, 82, 2943, 10.1182/blood.V82.10.2943.2943 Breit, 1993, Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T-cell receptor alpha/beta lineage: T-cell receptor delta gene deletion mechanism affects multiple genes, J. Exp. Med., 177, 965, 10.1084/jem.177.4.965 Reichel, 2001, Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL, Oncogene, 20, 2900, 10.1038/sj.onc.1204401 Alessandri, 2002, ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype, Br. J. Haematol., 116, 266, 10.1046/j.1365-2141.2002.03291.x Bernard, 2001, A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia, Leukemia, 15, 1495, 10.1038/sj.leu.2402249 Gleissner, 2001, Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data, Leukemia, 15, 1834, 10.1038/sj.leu.2402304 Uckun, 1997, Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children’s Cancer Group Study, Blood, 89, 3769, 10.1182/blood.V89.10.3769 Faderl, 1999, The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia, Clin. Cancer Res., 5, 1855 Faderl, 1999, Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia, Clin. Cancer Res., 5, 4041 Nakase, 2000, Dominant negative isoform of the Ikaros gene in patients with adult B-cell acute lymphoblastic leukemia, Cancer Res., 60, 4062 Wong, 2000, Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications, Blood, 95, 1942, 10.1182/blood.V95.6.1942 Stock, 2000, Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia, Blood, 95, 2364 Svingen, 2000, Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia, Blood, 96, 3922, 10.1182/blood.V96.12.3922 Albitar, 2001, Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia, Leuk. Res., 25, 859, 10.1016/S0145-2126(01)00042-X Chim, 2001, Methylation of p15 and p16 genes in adult acute leukemia: lack of prognostic significance, Cancer, 91, 2222, 10.1002/1097-0142(20010615)91:12<2222::AID-CNCR1252>3.0.CO;2-R Kuittinen, 2001, MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL), Leuk. Res., 25, 125, 10.1016/S0145-2126(00)00104-1 Roman, 2001, Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome, Br. J. Haematol., 113, 329, 10.1046/j.1365-2141.2001.02764.x Soenen, 2001, Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype, Leukemia, 15, 1054, 10.1038/sj.leu.2402153 Ballerini, 2002, HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis, Blood, 100, 991, 10.1182/blood-2001-11-0093 Hoshino, 2002, The absence of the p15INK4B gene alterations in adult patients with precursor B-cell acute lymphoblastic leukaemia is a favourable prognostic factor, Br. J. Haematol., 117, 531, 10.1046/j.1365-2141.2002.03451.x Roman-Gomez, 2002, 5′ cp. island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia, Blood, 99, 2291, 10.1182/blood.V99.7.2291 Ferrando, 2002, Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia, Cancer Cell, 1, 75, 10.1016/S1535-6108(02)00018-1 Chan, 1985, Contribution of immunophenotype to the classification and differential diagnosis of acute leukaemia, Lancet, 1, 475, 10.1016/S0140-6736(85)92085-9 Browman, 1986, The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukemia, Blood, 68, 900, 10.1182/blood.V68.4.900.900 Gassmann, 1997, Morphological and cytochemical findings in 150 cases of T-lineage acute lymphoblastic leukaemia in adults. German Multicentre ALL Study Group (GMALL), Br. J. Haematol., 97, 372, 10.1046/j.1365-2141.1997.d01-2171.x Heil, 1991, Ultrastructural demonstration of peroxidase expression in acute unclassified leukemias: correlation to immunophenotype and treatment outcome, Blood, 77, 1305, 10.1182/blood.V77.6.1305.1305 Buccheri, 1992, The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry, Br. J. Haematol., 80, 62, 10.1111/j.1365-2141.1992.tb06401.x Arber, 2001, Myeloperoxidase immunoreactivity in adult acute lymphoblastic leukemia, Am. J. Clin. Pathol., 116, 25, 10.1309/HDUE-DN2E-B72E-JK99 Vainchenker, 1988, Immunophenotype of leukemic blasts with small peroxidase-positive granules detected by electron microscopy, Leukemia, 2, 274 Serrano, 1999, Genetic, phenotypic and clinical features of acute lymphoblastic leukemias expressing myeloperoxidase mRNA detected by RT-PCR, Leukemia, 13, 175, 10.1038/sj.leu.2401305 Kantarjian, 1990, Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy, Blood, 76, 808, 10.1182/blood.V76.4.808.808 Hans, 2002, Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia, Am. J. Clin. Pathol., 117, 301, 10.1309/RWCG-E5T9-GU95-LEWE Faber, 2000, Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia, Arch. Pathol. Lab. Med., 124, 92, 10.5858/2000-124-0092-TDTNAL Paietta, 2001, Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity, Am. J. Hematol., 66, 189, 10.1002/1096-8652(200103)66:3<189::AID-AJH1043>3.0.CO;2-A Henderson ES. Clinical manifestation and diagnosis. In: Henderson ES, Lister TA, editors. Leukemia. 5th ed. Philadelphia: WB Sanders; 1990. p. 291–359. Hoelzer D. Diagnosis and treatment of adult acute lymphoblastic leukemia. In: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, editors. Neoplastic diseases of the blood. 2nd ed. New York: Churchill-Livingstone; 1991. p. 253–303. Gur, 1999, Rheumatic manifestations preceding adult acute leukemia: characteristics and implication in course and prognosis, Acta Haematol., 101, 1, 10.1159/000040913 Porcu, 2000, Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management, Leuk. Lymphoma, 39, 1, 10.3109/10428190009053534 Cohen, 1980, Acute tumor lysis syndrome. A review of 37 patients with Burkitt’s lymphoma, Am. J. Med., 68, 486, 10.1016/0002-9343(80)90286-7 Bain BJ. Leukemia diagnosis. A guide to the FAB classification. Philadelphia: JB Lippincott; 1990. Thomas, 2002, Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors, Leuk. Res., 26, 909, 10.1016/S0145-2126(02)00034-6 Fenaux, 2001, Burkitt’s acute lymphocytic leukemia (L3ALL) in adults, Hematol. Oncol. Clin. North Am., 15, 37, 10.1016/S0889-8588(05)70199-4 Chessells, 1995, Risk analysis in acute lymphoblastic leukaemia: problems and pitfalls, Eur. J. Cancer, 31A, 1656, 10.1016/0959-8049(95)00343-H Baccarani, 1982, Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients, Blood, 60, 677, 10.1182/blood.V60.3.677.677 Taylor, 1992, Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome, Blood, 80, 1813, 10.1182/blood.V80.7.1813.1813 Perentesis, 1997, Why is age such an important independent prognostic factor in acute lymphoblastic leukemia?, Leukemia, 11, S4 Chessells, 1998, The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties, Leukemia, 12, 463, 10.1038/sj.leu.2400959 Stiller, 1999, Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study, Br. J. Cancer, 79, 658, 10.1038/sj.bjc.6690104 Levi, 2000, Trends in mortality from leukemia in subsequent age groups, Leukemia, 14, 1980, 10.1038/sj.leu.2401915 Crist, 1988, Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis--a Pediatric Oncology Group Study, J. Clin. Oncol., 6, 34, 10.1200/JCO.1988.6.1.34 Santana, 1990, Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia, Leukemia, 4, 87 Nachman, 1993, Young adults 16–21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment, Cancer, 71, 3377, 10.1002/1097-0142(19930515)71:10+<3377::AID-CNCR2820711741>3.0.CO;2-8 van den, 2000, Acute lymphoblastic leukaemia in puberty and adolescence, Ann. Oncol., 11, 1375, 10.1023/A:1026538713236 Kantarjian, 1994, Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen, Br. J. Haematol., 88, 94, 10.1111/j.1365-2141.1994.tb04982.x Ferrari, 1995, Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period, Leukemia, 9, 1643 Pagano, 2000, Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study, Haematologica, 85, 1327 Faderl, 2002, Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission, Br. J. Haematol., 117, 869, 10.1046/j.1365-2141.2002.03506.x Mirro, 1986, Clinical and laboratory characteristics of acute leukemia with the 4;1 translocation, Blood, 67, 689, 10.1182/blood.V67.3.689.689 Ludwig, 1998, Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89, Blood, 92, 1898 Thiel, 1989, Prethymic phenotype and genotype of pre-T (CD7+/ER−)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia, Blood, 73, 1247, 10.1182/blood.V73.5.1247.1247 Garand, 1993, Characteristics of pro-T ALL subgroups: comparison with late T-ALL. The Groupe d’Etude Immunologique des Leucemies, Leukemia, 7, 161 Digel, 1994, Poor prognosis of prethymic phenotype acute lymphoblastic leukemia (pre-T-ALL), Leukemia, 8, 1406 Drexler, 1991, Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia, Leukemia, 5, 637 Sobol, 1987, Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia, N. Engl. J. Med., 316, 1111, 10.1056/NEJM198704303161802 Ball, 1991, Prognostic value of lymphocyte surface markers in acute myeloid leukemia, Blood, 77, 2242, 10.1182/blood.V77.10.2242.2242 Boldt, 1994, Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience, Leukemia, 8, 2118 Thomas, 1995, CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia, Leukemia, 9, 249 Boucheix, 1994, Immunophenotype of adult acute lymphoblastic leukemia clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia, Blood, 84, 1603, 10.1182/blood.V84.5.1603.bloodjournal8451603 Secker-Walker, 1991, Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance, Leukemia, 5, 196 Westbrook, 1992, Clinical significance of the BCR–ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762), Blood, 80, 2983, 10.1182/blood.V80.12.2983.2983 Barrett, 1992, Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia, Blood, 79, 3067, 10.1182/blood.V79.11.3067.3067 Grigg, 1993, Approaches to the treatment of Philadelphia-positive acute lymphoblastic leukemia, Bone Marrow Transplant, 12, 431 Annino, 1994, Adult Philadelphia-chromosome-positive acute lymphoblastic leukemia: experience of treatments during a ten-year period, Leukemia, 8, 664 Preti, 1994, Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients, Am. J. Med., 97, 60, 10.1016/0002-9343(94)90049-3 Rieder, 1996, Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia, Br. J. Haematol., 95, 678, 10.1046/j.1365-2141.1996.d01-1968.x Westbrook, 1997, Molecular subsets and prognostic factors in acute lymphoblastic leukemia, Leukemia, 11, S8 Arico, 2000, Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia, N. Engl. J. Med., 342, 998, 10.1056/NEJM200004063421402 Bassan, 2000, Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR–ABL rearrangements in B-precursor adult acute lymphoblastic leukemia, Hematol. J., 1, 226, 10.1038/sj.thj.6200032 Faderl, 2000, Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia, Leuk. Lymphoma, 36, 263, 10.3109/10428190009148847 Radich, 2001, Philadelphia chromosome-positive acute lymphocytic leukemia, Hematol. Oncol. Clin. North Am., 15, 21, 10.1016/S0889-8588(05)70198-2 Gleissner, 2002, Leading prognostic relevance of the BCR–ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis, Blood, 99, 1536, 10.1182/blood.V99.5.1536 Gekeler, 1992, Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias, Br. J. Cancer, 66, 507, 10.1038/bjc.1992.304 Miwa, 1993, Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia, Blood, 82, 3445, 10.1182/blood.V82.11.3445.3445 Goasguen, 1993, Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications, Blood, 81, 2394, 10.1182/blood.V81.9.2394.2394 Russo, 1994, Coexpression of anionic glutathione-S-transferase (GST pi) and multidrug resistance (mdr1) genes in acute myeloid and lymphoid leukemias, Leukemia, 8, 881 Damiani, 2002, P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia, Br. J. Haematol., 116, 519, 10.1046/j.0007-1048.2001.03322.x Tafuri, 2002, MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia, Blood, 100, 974, 10.1182/blood-2001-12-0371 Burger, 1994, Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias, Leukemia, 8, 990 Beck, 1995, Expression of mdr1 mrp topoisomerase II alpha/beta and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias, Br. J. Haematol., 89, 356, 10.1111/j.1365-2141.1995.tb03312.x Trippett, 1992, Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia, Blood, 80, 1158, 10.1182/blood.V80.5.1158.1158 Pieters, 1992, Adenosine deaminase and purine nucleoside phosphorylase in childhood lymphoblastic leukemia: relation with differentiation stage, in vitro drug resistance and clinical prognosis, Leukemia, 6, 375 Goker, 1993, Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease, Leukemia, 7, 1000 Joncourt, 1993, Cytostatic drug resistance: parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine–DNA–alkyltransferase and P-glycoprotein in adult patients with leukaemia, Br. J. Haematol., 85, 103, 10.1111/j.1365-2141.1993.tb08652.x Hall, 1994, Expression of mu class glutathione-S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia, Cancer Res., 54, 5251 Goker, 1995, Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations, Blood, 86, 677, 10.1182/blood.V86.2.677.bloodjournal862677 Gorlick, 1997, Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression, Blood, 89, 1013, 10.1182/blood.V89.3.1013 Schrappe, 1998, Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome, Blood, 92, 2730 Estlin, 2000, Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia, Br. J. Haematol., 110, 29, 10.1046/j.1365-2141.2000.02028.x Estlin, 2000, The clinical and cellular pharmacology of vincristine, corticosteroids, l-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia, Br. J. Haematol., 110, 780, 10.1046/j.1365-2141.2000.t01-1-02153.x Styczynski, 2000, In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia, Br. J. Haematol., 110, 813, 10.1046/j.1365-2141.2000.02211.x Rots, 2000, Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia, Br. J. Haematol., 110, 791, 10.1046/j.1365-2141.2000.02070.x Whitehead, 2001, The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study, Leukemia, 15, 1081, 10.1038/sj.leu.2402165 Schmiegelow, 2001, Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance, Leukemia, 15, 1066, 10.1038/sj.leu.2402144 Maung, 1995, Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia, Br. J. Haematol., 91, 93, 10.1111/j.1365-2141.1995.tb05251.x Remakers-van Woerden, 2002, In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups, Med. Pediatr. Oncol., 38, 379, 10.1002/mpo.10087 Evans, 1998, Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia, N. Engl. J. Med., 338, 499, 10.1056/NEJM199802193380803 Wattel, 1994, p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies, Blood, 84, 3148, 10.1182/blood.V84.9.3148.3148 Hsiao, 1994, Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase, Blood, 83, 2922, 10.1182/blood.V83.10.2922.2922 Lanza, 1995, p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints at 11q23 and 8q24, Leukemia, 9, 955 Debatin, 1995, Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program, Leukemia, 9, 815 Hangaishi, 1996, Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies, Blood, 87, 4949, 10.1182/blood.V87.12.4949.bloodjournal87124949 Tsai, 1996, Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies, Leukemia, 10, 1901 Miller, 1991, Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation, Blood, 78, 1125, 10.1182/blood.V78.4.1125.1125 Potter, 1993, Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review, Leukemia, 7, 1302 Pui, 2000, New definition of remission in childhood acute lymphoblastic leukemia, Leukemia, 14, 783, 10.1038/sj.leu.2401780 Uckun, 1993, Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia, N. Engl. J. Med., 329, 1296, 10.1056/NEJM199310283291802 Schultz, 1989, The contribution of residual leukemic cells in the graft to leukemia relapse after autologous bone marrow transplantation: mathematical considerations, Leukemia, 3, 530 Nagafuji, 1993, Evaluation of leukaemic contamination in peripheral blood stem cell harvests by reverse transcriptase polymerase chain reaction, Br. J. Haematol., 85, 578, 10.1111/j.1365-2141.1993.tb03351.x Seriu, 1995, Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation, Leukemia, 9, 615 Mizuta, 1999, Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group, Bone Marrow Transplant, 24, 777, 10.1038/sj.bmt.1701976 Campana, 1995, Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance, Blood, 85, 1416, 10.1182/blood.V85.6.1416.bloodjournal8561416 Knechtli, 1998, Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia, Blood, 92, 4072, 10.1182/blood.V92.11.4072 Chen, 2001, Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia, Blood, 97, 2115, 10.1182/blood.V97.7.2115 Estrov, 1986, Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission, N. Engl. J. Med., 315, 538, 10.1056/NEJM198608283150902 Brisco, 1996, Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia, Blood, 87, 5251, 10.1182/blood.V87.12.5251.bloodjournal87125251 Goulden, 1998, Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia, Br. J. Haematol., 100, 235, 10.1046/j.1365-2141.1998.00574.x Roberts, 1997, Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia, N. Engl. J. Med., 336, 317, 10.1056/NEJM199701303360501 van Dongen, 1998, Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood, Lancet, 352, 1731, 10.1016/S0140-6736(98)04058-6 Cave H, van der Werff ten Bosch, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med 1998;339:591–8. Coustan-Smith, 2000, Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia, Blood, 96, 2691, 10.1182/blood.V96.8.2691 Panzer-Grumayer, 2000, Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia, Blood, 95, 790, 10.1182/blood.V95.3.790.003k48_790_794 Stock W, Estrov Z. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000;14:1289-12ix. Brueggermann M, Droese J, Raff T, et al. The prognostic significance of minimal residual disease in adult standard risk patients with acute lymphoblastic leukemia. 2001;98:314a [abstract 1326]. Malec, 2001, Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL, Leukemia, 15, 716, 10.1038/sj.leu.2402091 Mortuza, 2002, Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia, J. Clin. Oncol., 20, 1094, 10.1200/JCO.20.4.1094 Nyvold, 2002, Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome, Blood, 99, 1253, 10.1182/blood.V99.4.1253 Anastasi, 1991, Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia, Blood, 77, 2456, 10.1182/blood.V77.11.2456.2456 Kasprzyk, 1997, Increased sensitivity of minimal residual disease detection by interphase FISH in acute lymphoblastic leukemia with hyperdiploidy, Leukemia, 11, 429, 10.1038/sj.leu.2400589 Kallakury, 1999, Posttherapy surveillance of B-cell precursor acute lymphoblastic leukemia. Value of polymerase chain reaction and limitations of flow cytometry, Am. J. Clin. Pathol., 111, 759, 10.1093/ajcp/111.6.759 Ciudad, 1998, Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia, J. Clin. Oncol., 16, 3774, 10.1200/JCO.1998.16.12.3774 Ciudad, 1999, Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL, Br. J. Haematol., 104, 695, 10.1046/j.1365-2141.1999.01236.x Griesinger, 1999, Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome, Br. J. Haematol., 105, 241, 10.1111/j.1365-2141.1999.01300.x Lucio, 1999, Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL, Leukemia, 13, 419, 10.1038/sj.leu.2401279 Middleton, 2000, Population-based study of the pattern of molecular markers of minimal residual disease in childhood and adult acute lymphoblastic leukemia: an assessment of the practical difficulty of representative sampling for trial purposes. Northern Region Haematology Group, Med. Pediatr. Oncol., 34, 106, 10.1002/(SICI)1096-911X(200002)34:2<106::AID-MPO6>3.0.CO;2-L Lucio, 2001, BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation, Leukemia, 15, 1185, 10.1038/sj.leu.2402150 Coustan-Smith, 2002, Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia, Blood, 100, 2399, 10.1182/blood-2002-04-1130 Dworzak, 2002, Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia, Blood, 99, 1952, 10.1182/blood.V99.6.1952 Sanchez, 2002, Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation, Br. J. Haematol., 116, 686, 10.1111/j.1365-2141.2002.3311a.x Kwan, 2000, Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction, Br. J. Haematol., 109, 430, 10.1046/j.1365-2141.2000.02029.x Janssen, 1994, Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission, Blood, 84, 3835, 10.1182/blood.V84.11.3835.bloodjournal84113835 Foroni, 1997, Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response, Leukemia, 11, 1732, 10.1038/sj.leu.2400841 Pongers-Willemse, 1998, Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes, Leukemia, 12, 2006, 10.1038/sj.leu.2401246 Szczepanski, 1998, Immunoglobulin and T-cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease, Leukemia, 12, 1081, 10.1038/sj.leu.2401071 Foroni, 1999, Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis, Br. J. Haematol., 105, 7, 10.1111/j.1365-2141.1999.01365.x Neale, 1999, Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia, Leukemia, 13, 1221, 10.1038/sj.leu.2401459 Brumpt, 2000, The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype, Blood, 96, 2254, 10.1182/blood.V96.6.2254 Cimino, 2000, A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia, Blood, 95, 96 Nakao, 2000, Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology, Cancer Res., 60, 3281 de, 2000, Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia, Br. J. Haematol., 111, 1080, 10.1046/j.1365-2141.2000.02434.x Donovan, 2000, Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia, Blood, 95, 2651, 10.1182/blood.V95.8.2651 Szczepanski, 2000, T-cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia refelct ‘end-stage’ recombinations: implications for minimal residual disease monitoring, Leukemia, 14, 1208, 10.1038/sj.leu.2401765 Nirmala, 2002, PCR-heteroduplex analysis of TCR gamma, delta and TAL-1 deletions in T-acute lymphoblastic leukemias: implications in the detection of minimal residual disease, Leuk. Res., 26, 335, 10.1016/S0145-2126(01)00130-8 van dV, 2002, Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL, Leukemia, 16, 1432, 10.1038/sj.leu.2402636 van dV, 2002, Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR, Leukemia, 16, 928, 10.1038/sj.leu.2402475 Willemse, 2002, Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL, Blood, 99, 4386, 10.1182/blood.V99.12.4386 van Rhee, 1995, Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow, Leukemia, 9, 329 Radich, 1997, Advances in the detection of minimal residual disease, Curr. Opin. Hematol., 4, 242, 10.1097/00062752-199704040-00004 Preudhomme, 1997, Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL), Leukemia, 11, 294, 10.1038/sj.leu.2400567 Mitterbauer, 1999, Quantification of minimal residual disease in patients with BCR–ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction, Br. J. Haematol., 106, 634, 10.1046/j.1365-2141.1999.01605.x Dombret, 2002, Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial, Blood, 100, 2357, 10.1182/blood-2002-03-0704 Yokota, 2002, Quantification of minimal residual disease in patients with e1a2 BCR–ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay, Leukemia, 16, 1167, 10.1038/sj.leu.2402483 Biondi, 2000, Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group, Leukemia, 14, 1939, 10.1038/sj.leu.2401922 Barnett, 1986, Treatment of acute lymphoblastic leukaemia in adults, Br. J. Haematol., 64, 455, 10.1111/j.1365-2141.1986.tb02201.x Gaynor, 1988, A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969, J. Clin. Oncol., 6, 1014, 10.1200/JCO.1988.6.6.1014 Hoelzer, 1993, Results of intensofied consolidation therapy in four consecutive German multicentre studies for adult ALL, Blood, 82, 193a Hoelzer, 1988, Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults, Blood, 71, 123, 10.1182/blood.V71.1.123.123 Hussein, 1989, Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy, Blood, 73, 57, 10.1182/blood.V73.1.57.57 Kantarjian, 1990, Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia, J. Clin. Oncol., 8, 994, 10.1200/JCO.1990.8.6.994 Linker, 1991, Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report, Blood, 78, 2814, 10.1182/blood.V78.11.2814.2814 Lluesma-Gonalons, 1991, Improved results of an intensified therapy in adult acute lymphocytic leukemia, Ann. Oncol., 2, 33, 10.1093/oxfordjournals.annonc.a057821 Larson, 1995, A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811, Blood, 85, 2025, 10.1182/blood.V85.8.2025.bloodjournal8582025 Linker, 1997, Risk-adapted treatment of adult acute lymphoblastic leukemia (ALL), Leukemia, 11, S24 Gokbuget, 2000, Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL), Hematol. Oncol. Clin. North Am., 14, 1307, 10.1016/S0889-8588(05)70188-X Goekbuget, 2001, Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05/93.802a, Blood, 98, 802a Bassan, 2001, Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups, Hematol. J., 2, 117, 10.1038/sj.thj.6200091 Gottlieb, 1984, Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B, Blood, 64, 267, 10.1182/blood.V64.1.267.267 Stryckmans, 1992, Therapy of adult ALL: overview of 2 successive EORTC studies: (ALL-2 & ALL-3). The EORTC Leukemia Cooperative Study Group, Leukemia, 6, 199 Bassan, 1992, Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period, Leukemia, 6, 186 Bassan, 1995, Institutional performance and dose intensity as prognostic factors in adult ALL, Leukemia, 9, 933 Candelaria, 1993, Adult acute lymphoblastic leukemia (AALL). Comparison of weekly doxorubicin (WD) vs. three day schedule (TDS) for induction remission. Long-term results, Blood, 82, 56a Koc, 1998, Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: results of two consecutive phase II clinical studies, Cancer Invest., 16, 355, 10.3109/07357909809115774 Hunault-Berger, 2001, Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study, Leukemia, 15, 898, 10.1038/sj.leu.2402130 Fiere, 1993, Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia, J. Clin. Oncol., 11, 1990, 10.1200/JCO.1993.11.10.1990 Cuttner, 1991, Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study, Leukemia, 5, 425 Bassan, 1993, Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome, Leuk. Lymphoma, 11, 105, 10.3109/10428199309054736 Bassan, 1999, Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia, Br. J. Haematol., 104, 755, 10.1046/j.1365-2141.1999.01258.x Ifrah, 1999, Intensive short-term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group, Cancer, 86, 1496, 10.1002/(SICI)1097-0142(19991015)86:8<1496::AID-CNCR16>3.0.CO;2-# Berman, 1992, Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells, Blood, 79, 3267, 10.1182/blood.V79.12.3267.3267 Weiss, 1993, Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia, Leukemia, 7, 832 Wernli, 1994, The limit of dose-intensification in the treatment of sdult acute lymphoblastic leukemia despite grow-factor therapy, Blood, 81, 144a Todeschini, 1994, Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia, Leukemia, 8, 376 Todeschini, 1998, Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin, Leukemia, 12, 144, 10.1038/sj.leu.2400912 Todeschini, 2001, High-dose anthracycline induction in adult acute lymphocytic leukemia, Hematol. Oncol. Clin. North Am., 15, 9, 10.1016/S0889-8588(05)70197-0 Takeuchi, 2002, Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study, Leukemia, 16, 1259, 10.1038/sj.leu.2402526 Kantarjian HM. Adult acute lymphocytic leukemia. Future research directions. Hematol Oncol Clin North Am 2001;15:207–11, viii. Nagura, 1994, Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without l-asparaginase for adult acute lymphoblastic leukemia, Cancer Chemother Pharmacol., 33, 359, 10.1007/BF00686263 Mandelli, 1992, GIMEMA ALL 0288: a multicentric study on adult acute lymphoblastic leukemia. Preliminary results, Leukemia, 6, 182 Thomas, 1995, Sequential induction chemotherapy with vincristine, daunorubicin, cyclophosphamide, and prednisone in adult acute lymphoblastic leukemia, Ann. Hematol., 70, 65, 10.1007/BF01834381 Durrant, 1997, Intensification of treatment for adults with acute lymphoblastic leukaemia: results of UK Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults, Br. J. Haematol., 99, 84, 10.1046/j.1365-2141.1997.3613175.x Gore, 1998, A phase II “window” study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia, Clin. Cancer Res., 4, 2677 Ueda, 1998, Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group, Int. J. Hematol., 68, 279, 10.1016/S0925-5710(98)00075-9 Daenen, 1998, Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a ‘pre-induction’ course for rapid tumour reduction: preliminary results on 66 patients, Br. J. Haematol., 100, 273, 10.1046/j.1365-2141.1998.00559.x Kobayashi, 1999, Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group, Jpn. J. Clin. Oncol., 29, 340, 10.1093/jjco/29.7.340 Bassan, 1999, Fractionated cyclophosphamide added to the IVAP regimen (idarubicin–vincristine–l-asparaginase–prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study, Haematologica, 84, 1088 Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am 2000;14:1367–79, x. Kantarjian, 2000, Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia, J. Clin. Oncol., 18, 547, 10.1200/JCO.2000.18.3.547 Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000;14:1381-13xi. Cataland, 2001, Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia, Leuk. Lymphoma, 41, 297, 10.3109/10428190109057984 Annino, 2002, Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study, Blood, 99, 863, 10.1182/blood.V99.3.863 Hallbook, 2002, High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia, Br. J. Haematol., 118, 748, 10.1046/j.1365-2141.2002.03685.x Larson, 1998, Hypersensitivity reactions to l-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia, Leukemia, 12, 660, 10.1038/sj.leu.2401007 Abshire, 2000, Weekly polyethylene glycol conjugated l-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study, Blood, 96, 1709, 10.1182/blood.V96.5.1709 Aguayo, 1999, Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia, Cancer, 86, 1203, 10.1002/(SICI)1097-0142(19991001)86:7<1203::AID-CNCR15>3.0.CO;2-3 Kantarjian, 1993, Modified Burkitt regimen for adult acute lymphocytic leukemia (ALL), Blood, 82, 329a Hoelzer, 1993, Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group, Leukemia, 7, S130 Kantarjian, 1993, Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia, Blood, 81, 1146, 10.1182/blood.V81.5.1146.1146 Rohatiner, 1990, High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia, Br. J. Cancer, 62, 454, 10.1038/bjc.1990.317 Weiss, 1996, Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone, J. Clin. Oncol., 14, 2480, 10.1200/JCO.1996.14.9.2480 Weiss, 2001, Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone, Hematol. Oncol. Clin. North Am., 15, 1, 10.1016/S0889-8588(05)70196-9 Magrath, 1996, Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen, J. Clin. Oncol., 14, 925, 10.1200/JCO.1996.14.3.925 Hoelzer, 1996, Improved outcome in adult B-cell acute lymphoblastic leukemia, Blood, 87, 495, 10.1182/blood.V87.2.495.bloodjournal872495 Lee, 2001, Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251, J. Clin. Oncol., 19, 4014, 10.1200/JCO.2001.19.20.4014 Cortes, 2002, Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia, Cancer, 94, 1492, 10.1002/cncr.10365 Ottmann, 1995, Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial, Blood, 86, 444, 10.1182/blood.V86.2.444.bloodjournal862444 Larson, 1998, A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111, Blood, 92, 1556 Geissler, 1997, Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia—a randomized phase-III study, Blood, 90, 590, 10.1182/blood.V90.2.590 Bassan, 1997, Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs, Leuk. Lymphoma, 26, 153, 10.3109/10428199709109170 Weiser, 2002, Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen, Cancer, 94, 285, 10.1002/cncr.10241 Inukai, 2000, Participation of granulocyte colony-stimulating factor in the growth regulation of leukemia cells from Philadelphia chromosome-positive acute leukemia and blast crisis of chronic myeloid leukemia, Leukemia, 14, 1386, 10.1038/sj.leu.2401837 Kobbe, 1998, Granulocyte colony-stimulating factor (G-CSF) mediated mobilization of leukemic cells in Philadelphia chromosome positive acute lymphoblastic leukemia expressing myeloid antigens (my + Ph + ALL), Am. J. Hematol., 58, 330, 10.1002/(SICI)1096-8652(199808)58:4<330::AID-AJH14>3.0.CO;2-B Hoelzer, 1994, Treatment of acute lymphoblastic leukemia, Semin Hematol., 31, 1 Marcus, 1986, Adult acute lymphoblastic leukaemia: a study of prognostic features and response to treatment over a ten year period, Br. J. Cancer, 53, 175, 10.1038/bjc.1986.32 Ribera, 1998, Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology, Haematologica, 83, 222 Petersdorf, 2001, Comparison of the L10 M consolidation regimen to an alternative regimen including escalating methotrexate/l-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study, Leukemia, 15, 208, 10.1038/sj.leu.2402006 Linker, 2002, Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia, J. Clin. Oncol., 20, 2464, 10.1200/JCO.2002.07.116 Ellison, 1991, The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B, J. Clin. Oncol., 9, 2002, 10.1200/JCO.1991.9.11.2002 Omura, 1980, Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis, Blood, 55, 199, 10.1182/blood.V55.2.199.199 Kantarjian, 1988, Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia, Blood, 72, 1784, 10.1182/blood.V72.5.1784.1784 Cortes, 1995, The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia, Blood, 86, 2091, 10.1182/blood.V86.6.2091.bloodjournal8662091 Gokbuget, 1998, Meningeosis leukaemica in adult acute lymphoblastic leukaemia, J. Neurooncol., 38, 167, 10.1023/A:1005963732481 Cortes, 2001, Central nervous system involvement in adult acute lymphocytic leukemia, Hematol. Oncol. Clin. North Am., 15, 145, 10.1016/S0889-8588(05)70203-3 Surapaneni, 2002, Central nervous system relapse in adults with acute lymphoblastic leukemia, Cancer, 94, 773, 10.1002/cncr.10265 Pinkel, 1994, Prevention and treatment of meningeal leukemia in children, Blood, 84, 355, 10.1182/blood.V84.2.355.355 Cassileth, 1992, Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience, Leukemia, 6, 178 Morra, 1986, Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin’s lymphoma, J Clin Oncol, 4, 1207, 10.1200/JCO.1986.4.8.1207 Wiernik, 1993, Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen, Leukemia, 7, 1236 Takayama, 2002, Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid, Br. J. Haematol., 119, 106, 10.1046/j.1365-2141.2002.03881.x Dekker, 1997, Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group, J. Clin. Oncol., 15, 476, 10.1200/JCO.1997.15.2.476 Patte, 1994, Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults, Baillieres Clin. Haematol., 7, 339, 10.1016/S0950-3536(05)80206-9 Bensinger, 1993, Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor, Blood, 81, 3158, 10.1182/blood.V81.11.3158.3158 Barrett, 1994, Bone marrow transplantation for acute lymphoblastic leukaemia, Baillieres Clin. Haematol., 7, 377, 10.1016/S0950-3536(05)80209-4 Fleming, 1996, Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study, Bone Marrow Transplant, 17, 917 Labar, 1996, Allogeneic bone marrow transplantation for acute leukaemia—IGCI experience. International Group for Chemo-Immunotherapy, Bone Marrow Transplant, 17, 1009 Frassoni, 1996, Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time—a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT), Bone Marrow Transplant, 17, 13 Appelbaum, 1997, Allogeneic hematopoietic stem cell transplantation for acute leukemia, Semin. Oncol., 24, 114 Weisdorf, 1997, Bone marrow transplantation for acute lymphocytic leukemia (ALL), Leukemia, 11, S20 Rowe, 1997, Bone marrow transplantation in first remission, Leukemia, 11, S12 Abdallah, 2001, Continuous complete remission in adult patients with acute lymphocytic leukaemia at a median observation of 12 years after autologous bone marrow transplantation, Br. J. Haematol., 112, 1012, 10.1046/j.1365-2141.2001.02634.x Molineux, 1990, Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor, Blood, 76, 2153, 10.1182/blood.V76.10.2153.2153 Makrynikola, 1991, Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation, Bone Marrow Transplant, 8, 351 Henon, 1992, Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants, Bone Marrow Transplant, 9, 285 To, 1992, Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants, Bone Marrow Transplant, 9, 277 Roberts, 1993, Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation, Bone Marrow Transplant, 12, 469 Langenmayer, 1995, Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both, Bone Marrow Transplant, 15, 241 Muroi, 2000, Autologous peripheral blood stem cell transplantation for adults with B-lineage acute lymphoblastic leukemia: a pilot study, Leuk. Lymphoma, 38, 103, 10.3109/10428190009060323 Appelbaum, 1997, Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL), Leukemia, 11, S15 Zikos, 1998, Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse, Haematologica, 83, 896 Passweg, 1998, Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia, Bone Marrow Transplant, 21, 153, 10.1038/sj.bmt.1701064 Cornelissen, 2001, Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome, Blood, 97, 1572, 10.1182/blood.V97.6.1572 Uzunel, 2001, The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia, Blood, 98, 1982, 10.1182/blood.V98.6.1982 Uckun, 1987, Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells, Blood, 69, 361, 10.1182/blood.V69.1.361.361 Preijers, 1989, Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma, Blood, 74, 1152, 10.1182/blood.V74.3.1152.1152 Uckun, 1990, Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging, Blood, 76, 1723, 10.1182/blood.V76.9.1723.1723 Morishima, 1993, Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement, Bone Marrow Transplant, 11, 255 Soiffer, 1993, Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse, Bone Marrow Transplant, 12, 243 Laporte, 1994, One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience, Blood, 84, 3810, 10.1182/blood.V84.11.3810.bloodjournal84113810 Rambaldi, 1998, Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation, Blood, 91, 2189, 10.1182/blood.V91.6.2189 Gilmore MJ, Hamon MD, Prentice HG, Katz F, IC, Hunter AE, et al. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant 1991;8:19–26. Hagenbeek, 1989, Cryopreservation of autologous marrow grafts in acute leukemia: survival of in vivo clonogenic leukemic cells and normal hemopoietic stem cells, Leukemia, 3, 535 Ramsay, 1985, Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement, Blood, 66, 508, 10.1182/blood.V66.3.508.508 Janossy, 1988, Autologous bone marrow transplantation in acute lymphoblastic leukemia--preclinical immunologic studies, Leukemia, 2, 485 Martin H, Atta J, Hoelzer D. Autologous BMT/PBSCT in BCR–ABL-positive ALL: rationale for purging. In: Dicke CA, Keating A, editors. Autologous blood and bone marrow transplantation. Carden Jennings Publishing Co.; 1999. p. 84–92. Granena, 1999, Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement, Bone Marrow Transplant, 24, 621, 10.1038/sj.bmt.1701957 Atta, 2000, Purging in BCR–ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs. peripheral blood stem cells by semiquantitative polymerase chain reaction, Bone Marrow Transplant, 25, 97, 10.1038/sj.bmt.1702096 Martin, 2001, Autologous stem cell transplantation for acute lymphocytic leukemia in adults, Hematol. Oncol. Clin. North Am., 15, 121, 10.1016/S0889-8588(05)70202-1 Gorin, 2002, Autologous stem cell transplantation in acute lymphocytic leukemia, Stem Cells, 20, 3, 10.1634/stemcells.20-1-3 Weyman, 1993, Use of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey, Bone Marrow Transplant, 11, 43 Deconinck, 1997, Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose ara-C and melphalan), Bone Marrow Transplant, 20, 731, 10.1038/sj.bmt.1700964 Labopin, 1995, Busulfan versus total body irradiation combined with cyclophosphamide as conditioning for autologous or allogenetic bone marrow transplantation in patients with acute leukemia, Blood, 86, 94a Hartman, 1998, Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs. total body irradiation: a meta-analysis, Bone Marrow Transplant, 22, 439, 10.1038/sj.bmt.1701334 Ringden, 1996, A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT), Br. J. Haematol., 93, 637, 10.1046/j.1365-2141.1996.d01-1681.x Shank R. Radiotherapeutic principles of bone marrow transplantation. In: Forman SJ, Blume KG, Thomas ED, editors. Bone marrow transplantation. Boston: Blackwell Scientific Publications; 1994. p. 96–113. Uckun, 1991, In vitro and in vivo radiation resistance associated with CD3 surface antigen expression in T-lineage acute lymphoblastic leukemia, Blood, 78, 2945, 10.1182/blood.V78.11.2945.2945 Uckun, 1993, Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts, Blood, 81, 1323, 10.1182/blood.V81.5.1323.1323 Kroger, 1998, Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia, Bone Marrow Transplant, 22, 1029, 10.1038/sj.bmt.1701498 Snyder, 1999, Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission, Leukemia, 13, 2053, 10.1038/sj.leu.2401589 Durrant, 2000, The Medical Research Council trials in adult acute lymphocytic leukemia, Hematol. Oncol. Clin. North Am., 14, 1327, 10.1016/S0889-8588(05)70189-1 Rowe, 2001, Favourable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): results from the international ALL trial (MRC UKALL XII/ECOG E2993), Blood, 98, 481a Pui, 2001, Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience, Semin. Hematol., 38, 13, 10.1016/S0037-1963(01)90039-3 Hughes, 2002, 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clin. Infect. Dis., 34, 730, 10.1086/339215 Bassan R. Management of infections in patients with leukemia. In: Henderson ES, Lister TA, Greaves MF, editors. Leukemia. 7th ed. Philadelphia: WB Saunders; 2002. p. 297–362. Hughes, 1990, From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever, J. Infect. Dis., 161, 381, 10.1093/infdis/161.3.381 Klastersky, 1993, Empirical antibiotic therapy in neutropenic cancer patients, Eur. J. Cancer, 29A, S6, 10.1016/S0959-8049(05)80253-9 Pizzo, 1993, Management of fever in patients with cancer and treatment-induced neutropenia, N. Engl. J. Med, 328, 1323, 10.1056/NEJM199305063281808 Karp, 1993, Management of infections in neutropenic patients: advances in therapy and prevention, Curr. Opin. Infect. Dis., 6, 405 Chanock, 1997, Infectious complications of patients undergoing therapy for acute leukemia: current status and future prospects, Semin. Oncol., 24, 132 Freifeld, 1995, Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem, J. Clin. Oncol., 13, 165, 10.1200/JCO.1995.13.1.165 Sanders, 1991, Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis, J. Infect. Dis., 164, 907, 10.1093/infdis/164.5.907 Ramphal, 1992, Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study, Antimicrob. Agents Chemother., 36, 1062, 10.1128/AAC.36.5.1062 EORTC. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991;163:951–8. Winston, 1993, Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial, Ann. Intern. Med., 118, 495, 10.7326/0003-4819-118-7-199304010-00003 Saral, 1983, Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study, Ann. Intern. Med., 99, 773, 10.7326/0003-4819-99-6-773 Gmur, 1991, Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia, Lancet, 338, 1223, 10.1016/0140-6736(91)92098-M Schiffer, 2001, Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology, J. Clin. Oncol., 19, 1519, 10.1200/JCO.2001.19.5.1519 Barbui, 1993, Bleeding and thrombosis in acute lymphoblastic leukemia, Leuk. Lymphoma, 11, 43, 10.3109/10428199309064261 Alberts, 1999, Thrombosis related to the use of l-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement, Leuk. Lymphoma, 32, 489, 10.3109/10428199909058406 Sarris, 1992, High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia, Blood, 79, 1305, 10.1182/blood.V79.5.1305.1305 Ottmann, 1996, Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia?, Leukemia, 10, 1111 Ottmann, 1998, Leuk. Res., 22, 1171, 10.1016/S0145-2126(98)00116-7 Hunault, 2001, Improved outcome of high risk acute lymphoblastic leukemia (ALL) with late high dose therapy. A GOLEAM’s trial, Blood, 98, 803a Linker, 2001, Autologous stem cell transplantation for high-risk adult acute lymphoblastic leukemia (ALL), Blood, 98, 689a Horowitz, 1991, Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission, Ann. Intern. Med., 115, 13, 10.7326/0003-4819-115-1-13 Sebban, 1994, Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia, J. Clin. Oncol., 12, 2580, 10.1200/JCO.1994.12.12.2580 Attal, 1995, Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group, Blood, 86, 1619, 10.1182/blood.V86.4.1619.bloodjournal8641619 Oh, 1998, Chemotherapy vs. HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission, Bone Marrow Transplant, 22, 253, 10.1038/sj.bmt.1701316 Thiebaut, 2000, Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87, Hematol. Oncol. Clin. North Am., 14, 1353, 10.1016/S0889-8588(05)70190-8 Thomas, 2001, Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period, Leukemia, 15, 1811, 10.1038/sj.leu.2402289 Ribera, 2000, Chemotherapy (CHT), allogenic (ALLO) or autologous (AUTO) stem cell transplantation (SCT) for high risk ALL (HRALL). Results of the ongoing protocol PETHEMA-93, Hematol. J., 1, 441a Gale, 1998, Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission, Leuk. Res., 22, 973, 10.1016/S0145-2126(98)00085-X Finiewicz, 1999, Dose-intensive therapy for adult acute lymphoblastic leukemia, Semin. Oncol., 26, 6 Powles, 1995, Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center, Bone Marrow Transplant, 16, 241 Forman, 1997, The role of allogeneic bone marrow transplantation in the treatment of high-risk acute lymphocytic leukemia in adults, Leukemia, 11, S18 Powles, 2002, The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia, Blood, 100, 1641, 10.1182/blood-2002-03-0776 Hoelzer, 1994, Therapy and prognostic factors in adult acute lymphoblastic leukaemia, Baillieres Clin. Haematol., 7, 299, 10.1016/S0950-3536(05)80204-5 Hoelzer, 2000, New approaches to acute lymphoblastic leukemia in adults: where do we go?, Semin. Oncol., 27, 540 Vernant, 1988, Allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia in first complete remission, J. Clin. Oncol., 6, 227, 10.1200/JCO.1988.6.2.227 Sutton, 1993, Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: factors predictive of transplant-related mortality and influence of total body irradiation modalities, Bone Marrow Transplant, 12, 583 Vey, 1994, Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission, Bone Marrow Transplant, 14, 383 Chao, 1991, Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission, Blood, 78, 1923, 10.1182/blood.V78.8.1923.1923 Lee, 2002, Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B-lineage acute lymphoblastic leukaemia in first or second remission, Br. J. Haematol., 117, 109, 10.1046/j.1365-2141.2002.03403.x Zhang, 1995, Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee, Ann. Intern. Med., 123, 428, 10.7326/0003-4819-123-6-199509150-00006 Sierra, 1993, Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients, Bone Marrow Transplant, 12, 517 Doney, 1993, Autologous bone marrow transplantation for acute lymphoblastic leukemia, Bone Marrow Transplant, 12, 315 Tiley, 1993, Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia, Bone Marrow Transplant, 12, 449 Carella, 1994, Autologous bone marrow transplantation in acute lymphoblastic leukaemia, Baillieres Clin. Haematol., 7, 403, 10.1016/S0950-3536(05)80210-0 Sotomayor, 2002, Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction ara-C dose and post-remission therapy, Leuk. Res., 26, 461, 10.1016/S0145-2126(01)00175-8 Szydlo, 1997, Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings, J. Clin. Oncol., 15, 1767, 10.1200/JCO.1997.15.5.1767 Marks, 1998, Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia, J. Clin. Oncol., 16, 931, 10.1200/JCO.1998.16.3.931 Arnold, 2002, Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease, Leukemia, 16, 2423, 10.1038/sj.leu.2402712 Aversa, 1996, Mismatched transplant for acute lymphoblastic leukemia, Bone Marrow Transplant, 18, 36 Annino, 2002, Acute lymphoblastic leukemia in the elderly, Hematol. J., 3, 219, 10.1038/sj.thj.6200189 Bassan, 1996, Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia, Leuk. Lymphoma, 22, 295, 10.3109/10428199609051761 Thomas, 2001, Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience, Am. J. Hematol., 67, 73, 10.1002/ajh.1083 Legrand, 1997, Prognostic factors in elderly acute lymphoblastic leukaemia, Br. J. Haematol., 97, 596, 10.1046/j.1365-2141.1997.952909.x Zuazu, 1991, Pregnancy outcome in hematologic malignancies, Cancer, 67, 703, 10.1002/1097-0142(19910201)67:3<703::AID-CNCR2820670329>3.0.CO;2-6 Durie, 1977, Successful treatment of acute leukemia during pregnancy. Combination therapy in the third trimester, Arch. Intern. Med., 137, 90, 10.1001/archinte.137.1.90 Fassas, 1984, Chemotherapy for acute leukemia during pregnancy. Five case reports, Nouv. Rev. Fr. Hematol., 26, 19 Hansen, 2001, Leukemia in pregnancy and fetal response to multiagent chemotherapy, Obstet. Gynecol., 97, 809, 10.1016/S0029-7844(00)01170-4 Chucrallah, 1995, Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes, Cancer, 76, 985, 10.1002/1097-0142(19950915)76:6<985::AID-CNCR2820760611>3.0.CO;2-G Arlin, 1982, Treatment of refractory adult lymphoblastic leukemia (ALL) with 4′(9-acridinylamino) methanesulfon-M-anisidide (AMSA), Blood, 60, 1224, 10.1182/blood.V60.5.1224.1224 Milpied, 1990, Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy, Cancer, 66, 627, 10.1002/1097-0142(19900815)66:4<627::AID-CNCR2820660404>3.0.CO;2-0 Freund, 1992, Treatment of relapsed or refractory adult acute lymphocytic leukemia, Cancer, 69, 709, 10.1002/1097-0142(19920201)69:3<709::AID-CNCR2820690318>3.0.CO;2-G Welborn, 1994, Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults, Am. J. Hematol., 45, 341, 10.1002/ajh.2830450413 Henze, 1995, Tailored therapy for relapsed or refractory childhood acute lymphoblastic leukemia, Leukemia, 9, 538 Weiss, 1997, Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL), Leukemia, 11, S28 Weiss, 1998, A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia, Leukemia, 12, 865, 10.1038/sj.leu.2401058 Giona, 1994, Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Associazione Italiana Ematologia ed Ocologia Pediatrica, Br. J. Haematol., 86, 55, 10.1111/j.1365-2141.1994.tb03252.x Kantarjian, 1992, Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia, Blood, 79, 876, 10.1182/blood.V79.4.876.bloodjournal794876 Giona, 1997, Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol, Br. J. Haematol., 97, 896, 10.1046/j.1365-2141.1997.1102926.x Hiddemann, 1990, Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM), Leukemia, 4, 637 Koller, 1997, The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia, Leukemia, 11, 2039, 10.1038/sj.leu.2400861 Montillo, 1997, Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF), Leuk. Lymphoma, 25, 579, 10.3109/10428199709039047 Giona, 1998, Management of advanced acute lymphoblastic leukemia in children and adults: results of the ALL R-87 protocol. AIEOP and GIMEMA Cooperative Groups, Leuk. Lymphoma, 32, 89, 10.3109/10428199809059249 Thomas, 1999, Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy, Cancer, 86, 1216, 10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O Martino, 1999, Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial, Haematologica, 84, 505 Rosen, 2000, A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia, Leuk. Res., 24, 183, 10.1016/S0145-2126(99)00148-4 Garcia-Manero, 2001, Salvage therapy for refractory or relapsed acute lymphocytic leukemia, Hematol. Oncol. Clin. North Am., 15, 163, 10.1016/S0889-8588(05)70204-5 Weiss, 2002, A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia, Cancer, 95, 581, 10.1002/cncr.10707 Chao NJ, Forman SJ. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia. In: Forman SJ, Blume KJ, Thomas ED, editors. Bone marrow transplantation. Boston: Blackwell Scientific Publications; 1994. p. 618–39. Fleming, 1994, Prtially matched related donor (PMRD) allogenetic bone marrow transplantation (BMT) in recurrent acute lymphoblastic leukemia (ALL), Blood, 84, 214a Bassan, 1996, Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults, Haematologica, 81, 20 Busca, 1994, Unrelated donor or autologous marrow transplantation for treatment of acute leukemia, Blood, 83, 3077, 10.1182/blood.V83.10.3077.3077 Matthews, 1995, Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation, Blood, 85, 1122, 10.1182/blood.V85.4.1122.bloodjournal8541122 Cavazzana-Calvo, 1996, A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Societe Francaise de Greffe de Moelle Osseuse, Br. J. Haematol., 93, 131, 10.1046/j.1365-2141.1996.4831024.x Ager, 1995, Autologous bone marrow transplantation for second or greater complete remission of acute myeloid leukaemia and acute lymphoblastic leukaemia, Leuk. Lymphoma, 18, 349, 10.3109/10428199509059629 Carella, 1995, Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukaemia, Br. J. Haematol., 89, 535, 10.1111/j.1365-2141.1995.tb08360.x Deane, 1998, FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission, Bone Marrow Transplant, 22, 1137, 10.1038/sj.bmt.1701521 Martino, 1998, Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia, Bone Marrow Transplant, 21, 1023, 10.1038/sj.bmt.1701221 Mengarelli, 2002, Increasing risk of relapse after allogeneic stem cell transplant for adult acute lymphoblastic leukemia in > or = 2nd complete remission induced by highly intensive chemotherapy, Haematologica, 87, 782 Weisdorf, 1997, Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia, Blood, 90, 2962, 10.1182/blood.V90.8.2962 Kern, 2001, Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias, Ann. Hematol., 80, 334, 10.1007/s002770100293 Classen, 1999, Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity, Leukemia, 13, 410, 10.1038/sj.leu.2401335 Archimbaud, 1991, Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells, Leukemia, 5, 967 Lauria, 1994, In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival, Leukemia, 8, 724 Nemunaitis, 1997, Use of cytokines in the treatment of acute lymphoblastic leukemia, Leukemia, 11, S36 Cardoso, 1999, Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies, Blood, 94, 3531, 10.1182/blood.V94.10.3531.422k14_3531_3540 Velders, 2001, Prospect for immunotherapy of acute lymphoblastic leukemia, Leukemia, 15, 701, 10.1038/sj.leu.2402103 Gribben, 1997, Biologic response modifiers in acute lymphoblastic leukemia, Leukemia, 11, S31 Lowdell, 2002, Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells, Br. J. Haematol., 117, 821, 10.1046/j.1365-2141.2002.03495.x Visani, 2000, Alpha-interferon improves survival and remission duration in P-190BCR–ABL positive adult acute lymphoblastic leukemia, Leukemia, 14, 22, 10.1038/sj.leu.2401641 Beaujean, 1995, Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia, Bone Marrow Transplant, 15, 691 de Fabritis, 1995, In vitro purging with BCR–ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation, Leukemia, 9, 662 Slater, 1986, Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro, J. Clin. Invest., 77, 1405, 10.1172/JCI112450 Gonzalez, 1995, Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833, Cancer Chemother. Pharmacol., 36, 335, 10.1007/BF00689051 Jiang, 1995, Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833, Br. J. Haematol., 90, 375, 10.1111/j.1365-2141.1995.tb05162.x Lacerda, 1995, Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection, Blood, 85, 2675, 10.1182/blood.V85.10.2675.bloodjournal85102675 Gandhi, 1995, ARA-C modulation by fludarabine: a strategy to overcome resistance to ARA-C, Leukemia, 9, 529 Manabe, 1994, Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia, Blood, 83, 1731, 10.1182/blood.V83.7.1731.1731 Uckun, 1995, In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells, Blood, 85, 2817, 10.1182/blood.V85.10.2817.bloodjournal85102817 Giles, 2001, Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia, J. Clin. Oncol., 19, 762, 10.1200/JCO.2001.19.3.762 Karp, 2001, Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial, Blood, 97, 3361, 10.1182/blood.V97.11.3361 Uckun, 1999, Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor, Clin. Cancer Res., 5, 3906 Herrera, 2000, Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro, Leukemia, 14, 853, 10.1038/sj.leu.2401779 Jandula, 2001, Rituximab can be useful as treatment for minimal residual disease in bcr–abl-positive acute lymphoblastic leukemia, Bone Marrow Transplant, 27, 225, 10.1038/sj.bmt.1702706 de Vetten, 2000, Molecular remission of Philadelphia/bcr–abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676), Br. J. Haematol., 111, 277, 10.1046/j.1365-2141.2000.02402.x Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells, Nat. Med., 2, 561, 10.1038/nm0596-561 Druker, 2001, Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, N. Engl. J. Med., 344, 1038, 10.1056/NEJM200104053441402 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia, N. Engl. J. Med., 344, 1031, 10.1056/NEJM200104053441401 Ottmann, 2002, The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia—promises, pitfalls and possibilities, Hematol. J., 3, 2, 10.1038/sj.thj.6200151 Wassmann, 2002, Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL), Leukemia, 16, 2358, 10.1038/sj.leu.2402770 Thiesing, 2000, Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr–abl-positive cells, Blood, 96, 3195, 10.1182/blood.V96.9.3195 Fang, 2000, CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr–Abl-positive human leukemia cells to apoptosis due to antileukemic drugs, Blood, 96, 2246, 10.1182/blood.V96.6.2246 Tipping, 2002, Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs, Leukemia, 16, 2349, 10.1038/sj.leu.2402775 Topaly, 2002, Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies, Br. J. Haematol., 119, 3, 10.1046/j.1365-2141.2002.03806.x Visani, 2002, Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR–ABL)-positive acute lymphoblastic leukemia, Leukemia, 16, 2159, 10.1038/sj.leu.2402729 Branford, 2002, High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance, Blood, 99, 3472, 10.1182/blood.V99.9.3472 Hochhaus, 2002, Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy, Leukemia, 16, 2190, 10.1038/sj.leu.2402741 Hofmann, 2002, Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study, Lancet, 359, 481, 10.1016/S0140-6736(02)07678-X Bassan, 1991, Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia, Eur. J. Cancer, 27, 441, 10.1016/0277-5379(91)90382-N Chan, 2001, Long-term cerebral metabolite changes on proton magnetic resonance spectroscopy in patients cured of acute lymphoblastic leukemia with previous intrathecal methotrexate and cranial irradiation prophylaxis, Int. J. Radiat. Oncol. Biol. Phys., 50, 759, 10.1016/S0360-3016(01)01513-9 Kornblith, 1998, Comparison of psychosocial adaptation of advanced stage Hodgkin’s disease and acute leukemia survivors. Cancer and Leukemia Group B, Ann. Oncol., 9, 297, 10.1023/A:1008297130258 Ridgway, 1993, Active immunization of children with leukemia and other malignancies, Leuk. Lymphoma, 9, 177, 10.3109/10428199309147369 Socie G, Stone JV, Wingard JR, Weisdorf D, P.J., Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999;341:14–21. Deeg HJ. Delayed complications after bone marrow transplantation. In: Forman SJ, Blume KG, Thomas ED, editors. Bone transplantation. Boston: Blackwell Scientific Publications; 1994. p. 538–44. Pedersen-Bjergaard, 1991, Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II, Blood, 78, 1147, 10.1182/blood.V78.4.1147.1147 Pagano, 1998, Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto, Br. J. Haematol., 100, 669, 10.1046/j.1365-2141.1998.00616.x Micallef, 2001, Long-term outcome of patients surviving for more than ten years following treatment for acute leukaemia, Br. J. Haematol., 113, 443, 10.1046/j.1365-2141.2001.02788.x Pui, 1995, l-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins, Leukemia, 9, 1680 Winick, 1993, Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide, J. Clin. Oncol., 11, 209, 10.1200/JCO.1993.11.2.209